http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yuki Kambayashi (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Yusuke Umahashi,Yuki Kambayashi,Masaru Kato,Yohei Hasegawa,Hideharu Amano,Kimiyoshi Usami 대한전자공학회 2008 ITC-CSCC :International Technical Conference on Ci Vol.2008 No.7
When the dynamic reconfigurable processors run, a lot of Processing Elements (PE) are changed by the context which is written information of circuit configuration. Some PEs execute heavy operations, while other PEs execute light operation. Therefore, the delay time of each PE changes with the contexts. We propose a technique to dynamically change dual supply voltages at each PE. First, we calculate the delay of each PE under the context. Next, we define the standard delay. The standard delay is the longest delay of each PE. Then we assign the standard or lower voltage to each PE. If the PE’s delay at the lower voltage is longer than the standard, this PE is assigned the standard voltage. If shorter than the standard delay, this PE is assigned the lower voltage. Finally, we calculate the power consumption with the technique of dual supply voltage by using the number of assignment the each voltage. When the same voltage was assigned to, the power consumption was reduced by 18.7%. When the voltage is assigned PE-by-PE individually, the power consumption was reduced by 20.3%.
-
Masaya Igase,Sakuya Inanaga,Shoma Nishibori,Kazuhito Itamoto,Hiroshi Sunahara,Yuki Nemoto,Kenji Tani,Hiro Horikirizono,Munekazu Nakaichi,Kenji Baba,Satoshi Kambayashi,Masaru Okuda,Yusuke Sakai,Masashi 대한수의학회 2024 Journal of Veterinary Science Vol.25 No.1
Background: The anti-programmed death 1 (PD-1) antibody has led to durable clinical responses in a wide variety of human tumors. We have previously developed the caninized anti-canine PD-1 antibody (ca-4F12-E6) and evaluated its therapeutic properties in dogs with advance-staged oral malignant melanoma (OMM), however, their therapeutic effects on other types of canine tumors remain unclear. Objective: The present clinical study was carried out to evaluate the safety profile and clinical efficacy of ca-4F12-E6 in dogs with advanced solid tumors except for OMM. Methods: Thirty-eight dogs with non-OMM solid tumors were enrolled prospectively and treated with ca-4F12-E6 at 3 mg/kg every 2 weeks of each 10-week treatment cycle. Adverse events (AEs) and treatment efficacy were graded based on the criteria established by the Veterinary Cooperative Oncology Group. Results: One dog was withdrawn, and thirty-seven dogs were evaluated for the safety and efficacy of ca-4F12-E6. Treatment-related AEs of any grade occurred in 13 out of 37 cases (35.1%). Two dogs with sterile nodular panniculitis and one with myasthenia gravis and hypothyroidism were suspected of immune-related AEs. In 30 out of 37 dogs that had target tumor lesions, the overall response and clinical benefit rates were 6.9% and 27.6%, respectively. The median progression-free survival and overall survival time were 70 days and 215 days, respectively. Conclusions: The present study demonstrated that ca-4F12-E6 was well-tolerated in non-OMM dogs, with a small number of cases showing objective responses. This provides evidence supporting large-scale clinical trials of anti-PD-1 antibody therapy in dogs.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
